Although it is presently difficult to explain the apparent link between PD‐L1 expression and the TCRγδ phenotype of the tumor cells, future clinical trials should explore whether anti‐PD‐1/PD‐L1 therapies may improve our therapeutic approach for these aggressive diseases. Here, PDCD1 is linked to neoplasm.